Akari Therapeutics PLC: Rising Pharma Star Targeting Autoimmune & Inflammatory Drugs
Discover Akari Therapeutics PLC—London‑based anti‑inflammatory drug pioneer, trading on Nasdaq, poised to reshape autoimmune treatment markets.
2 minutes to read
AKARI THERAPEUTICS PLC
Akari Therapeutics Delays Q2 Report: Impairment Charge, Price Drop & SEC Extension
Akari Therapeutics delays quarterly filing, faces a non‑cash impairment and seeks a 5‑day SEC extension—what this means for its anti‑inflammatory drug strategy and investor outlook.
2 minutes to read